<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01025739</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00004475</org_study_id>
    <nct_id>NCT01025739</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD</brief_title>
  <official_title>Phase II Study of Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives of the Study:

      The primary objective of this study is to evaluate the relative merits, safety and
      effectiveness of the tailored TIF2 procedure in treating GERD patients who have persistent
      GERD symptoms despite PPI therapy.

      The secondary objective of the study is to evaluate the effectiveness of the tailored TIF
      procedure in restoring the antireflux barrier and eliminating GE reflux.

      Type of Study:

      Prospective, non-randomized, uncontrolled Study Duration 12 months Number of Patients 20

      Inclusion Criteria:

      Age 18-70 years, on daily PPIs for &gt; 6 months, persistent GERD symptoms despite PPI therapy,
      anatomic disruption of the gastroesophageal valve to a Hill Grade II-III, evidence of one of
      the following while on PPI therapy: (1) erosive esophagitis (erosions or ulcerations during
      endoscopy); (2) abnormal ambulatory pH study; or (3) biopsy confirmed changes characteristic
      of reflux esophagitis; acceptable esophageal motility (by either manometry or video
      esophagogram), hiatal hernia no larger than 2 cm, patient willing to cooperate with
      post-operative dietary recommendations and assessment tests, signed informed consent

      Exclusion Criteria:

      BMI &gt; 40, hiatal hernia &gt; 2 cm, esophagitis grade D, esophageal ulcer, fixed esophageal
      stricture, gastric motility disorders, previous splenectomy, pregnancy (female),
      immunosuppression, ASA &gt; 2, portal hypertension and/or varices, history of previous resective
      gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal
      epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis,
      or cirrhosis, active gastro-duodenal ulcer disease, gastric outlet obstruction or stenosis,
      gastroparesis or delayed gastric emptying, coagulation disorders

      Interventions:

      Treatment: Tailored transoral incisionless fundoplication (TIF2) using EsophyX system with
      SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA)

      Evaluation Criteria:

      Primary Outcome Measure 24 hour pH impedance study: change in Johnson DeMeester scores;
      GERD-HRQOL scores Secondary Outcome Measures PPI usage, GERD symptoms at 6 and 12 months vs.
      baseline off PPI's, total number of reflux episodes, and Symptom Association Probability
      while off PPI.

      Safety: Adverse events will be mapped to standard terms and reported.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding source for device purchasing
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour pH impedance study: change in Johnson DeMeester scores; GERD-HRQOL scores</measure>
    <time_frame>1, 3, 6, 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PPI usage, GERD symptoms at 6 and 12 months vs. baseline off PPI's, total number of reflux episodes, and Symptom Association Probability while off PPI. Safety: Adverse events will be mapped to standard terms and reported.</measure>
    <time_frame>1 day; 1 week; 1, 3, 6, 12 month</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroesophageal Reflux Disease (GERD)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EsophyX™ system with SerosaFuse fasteners</intervention_name>
    <description>The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-70 years

          -  On daily PPIs for &gt; 6 months

          -  Persistent GERD symptoms despite PPI therapy

          -  Anatomic disruption of the gastroesophageal valve to a Hill Grade II-III

          -  Evidence of one of the following while on PPI therapy:

               -  Erosive esophagitis (erosions or ulcerations during endoscopy)

               -  Abnormal ambulatory pH study

               -  Biopsy confirmed changes characteristic of reflux esophagitis

          -  Acceptable esophageal motility (by either manometry or video esophagogram)

          -  Hiatal hernia no larger than 2 cm

          -  Patient willing to cooperate with post-operative dietary recommendations and
             assessment tests

          -  Signed informed consent

        Exclusion Criteria:

          -  BMI &gt; 40

          -  Hiatal hernia &gt; 2 cm

          -  Esophagitis grade D

          -  Esophageal ulcer

          -  Esophageal stricture

          -  Esophageal motility disorder

          -  Prior splenectomy

          -  Pregnancy or plans for pregnancy in the next 12 months (in females)

          -  Immunosuppression

          -  ASA &gt; 2

          -  Portal hypertension and/or varices

          -  History of previous resective gastric or esophageal surgery, cervical spine fusion,
             Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or
             dermatomyositis, eosinophilic esophagitis, or cirrhosis

          -  Active gastro-duodenal ulcer disease

          -  Gastric outlet obstruction or stenosis

          -  Gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying
             study if patient complains of postprandial satiety during assessment

          -  Coagulation disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CAMIS, Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26. Epub 2006 Dec 4. Review.</citation>
    <PMID>17142109</PMID>
  </reference>
  <reference>
    <citation>Lundell L. Surgery of gastroesophageal reflux disease: a competitive or complementary procedure? Dig Dis. 2004;22(2):161-70. Review.</citation>
    <PMID>15383757</PMID>
  </reference>
  <reference>
    <citation>Metz DC. Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med. 2004 Sep 6;117 Suppl 5A:49S-55S. Review.</citation>
    <PMID>15478853</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006 Jun 24;367(9528):2086-100. Review.</citation>
    <PMID>16798392</PMID>
  </reference>
  <reference>
    <citation>Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol. 2000 Oct;14(5):743-57. Review.</citation>
    <PMID>11003807</PMID>
  </reference>
  <reference>
    <citation>Smout AJ. The patient with GORD and chronically recurrent problems. Best Pract Res Clin Gastroenterol. 2007;21(3):365-78. Review.</citation>
    <PMID>17544105</PMID>
  </reference>
  <reference>
    <citation>Stylopoulos N, Rattner DW. The history of hiatal hernia surgery: from Bowditch to laparoscopy. Ann Surg. 2005 Jan;241(1):185-93. Review.</citation>
    <PMID>15622007</PMID>
  </reference>
  <reference>
    <citation>Jones MP, Sloan SS, Rabine JC, Ebert CC, Huang CF, Kahrilas PJ. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol. 2001 Jun;96(6):1711-7.</citation>
    <PMID>11419819</PMID>
  </reference>
  <reference>
    <citation>Mittal RK. Hiatal hernia: myth or reality? Am J Med. 1997 Nov 24;103(5A):33S-39S. Review.</citation>
    <PMID>9422620</PMID>
  </reference>
  <reference>
    <citation>Mittal RK. Hiatal hernia and gastroesophageal reflux: another attempt to resolve the controversy. Gastroenterology. 1993 Sep;105(3):941-3.</citation>
    <PMID>8359662</PMID>
  </reference>
  <reference>
    <citation>Moss SF, Kidd M, Modlin IM. The status of the hiatus: the role of hernia in gastroesophageal reflux disease. J Clin Gastroenterol 2007;41:S144-S153</citation>
  </reference>
  <reference>
    <citation>Rydberg L, Ruth M, Lundell L. Mechanism of action of antireflux procedures. Br J Surg. 1999 Mar;86(3):405-10.</citation>
    <PMID>10201789</PMID>
  </reference>
  <reference>
    <citation>Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year. Obes Surg. 2005 May;15(5):641-7.</citation>
    <PMID>15946454</PMID>
  </reference>
  <reference>
    <citation>Cadière GB, Rajan A, Rqibate M, Germay O, Dapri G, Himpens J, Gawlicka AK. Endoluminal fundoplication (ELF)--evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol. 2006;15(6):348-55.</citation>
    <PMID>17190659</PMID>
  </reference>
  <reference>
    <citation>Jobe BA, O'Rourke RW, McMahon BP, Gravesen F, Lorenzo C, Hunter JG, Bronner M, Kraemer SJ. Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device. Ann Surg. 2008 Jul;248(1):69-76. doi: 10.1097/SLA.0b013e31817c9630.</citation>
    <PMID>18580209</PMID>
  </reference>
  <reference>
    <citation>Cadière GB, Rajan A, Germay O, Himpens J. Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility study. Surg Endosc. 2008 Feb;22(2):333-42. Epub 2007 Dec 11.</citation>
    <PMID>18071818</PMID>
  </reference>
  <reference>
    <citation>Cadière GB, Buset M, Muls V, Rajan A, Rösch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Devière J. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg. 2008 Aug;32(8):1676-88. doi: 10.1007/s00268-008-9594-9.</citation>
    <PMID>18443855</PMID>
  </reference>
  <reference>
    <citation>Huber-Lang M, Henne-Bruns D, Schmitz B, Wuerl P. Esophageal perforation: principles of diagnosis and surgical management. Surg Today. 2006;36(4):332-40.</citation>
    <PMID>16554990</PMID>
  </reference>
  <reference>
    <citation>Bouvy ND, Witteman BPL, Jobe BA, Lorenzo C, Kraemer SJM, Gawlicka AK, McMahon B, Gravesen FH, Masclee A, Hameeteman W, Koek GH, Perry K. Tailored reconstruction of the esophagogastric junction using transoral incisionless fundoplication: a feasibility study. Surg Endosc 2008</citation>
  </reference>
  <reference>
    <citation>Bouvy ND, Witteman BPL, de Vries E, van Dam JW, Greve JW, Gawlicka AK, Masclee A, Hameeteman W, Koek GH. EsophyX transoral incisionless fundoplication for the treatment of GERD in clinical practice. Surg Endosc 2008</citation>
  </reference>
  <reference>
    <citation>Bouvy ND, Witteman BPL, de Vries E, van Dam R, Greve JW, Gawlicka AK, Masclee A, Hameeteman W, Koek GH. EsophyX transoral incisionless fundoplication for the treatment of GERD in clinical practice. Gastrointest Endosc 2008</citation>
  </reference>
  <reference>
    <citation>Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80.</citation>
    <PMID>10403727</PMID>
  </reference>
  <reference>
    <citation>Jobe BA, Kahrilas PJ, Vernon AH, Sandone C, Gopal DV, Swanstrom LL, Aye RW, Hill LD, Hunter JG. Endoscopic appraisal of the gastroesophageal valve after antireflux surgery. Am J Gastroenterol. 2004 Feb;99(2):233-43.</citation>
    <PMID>15046210</PMID>
  </reference>
  <reference>
    <citation>Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE 2nd. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc. 1996 Nov;44(5):541-7.</citation>
    <PMID>8934159</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>April 27, 2015</last_update_submitted>
  <last_update_submitted_qc>April 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Daniel Birch</investigator_full_name>
    <investigator_title>MSc, MD, FRCSC, FACS</investigator_title>
  </responsible_party>
  <keyword>Gastroesophageal Reflux Disease (GERD)</keyword>
  <keyword>EsophyX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

